Impact of Exercise on Myasthenia Gravis: Insights from a Patient-Reported Survey on Activity Patterns and Effects - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Exercise on Myasthenia Gravis: Insights from a Patient-Reported Survey on Activity Patterns and Effects

  • By

  • Stefanie Glaubitz

  • Stefanie Meyer

  • Johanna Loris

  • Rachel Zeng

  • Karsten Kummer

  • Tania Garfias-Veitl

  • Ariana Seraji

  • Lina Hassoun

  • Denise Rohleder

  • Ina Hunger

  • Jana Zschüntzsch

  • December 17, 2025

Share

  • 1

    Myasthenia gravis (MG) is a chronic autoimmune disorder that leads to fluctuating muscle weakness due to impaired neuromuscular transmission.

  • 2

    Regular physical activity is associated with improved cardiovascular health and quality of life in individuals with autoimmune diseases, including MG.

  • 3

    Current evidence supports that exercise is safe for individuals with mild to moderate MG, aligning with standard guidelines of 150 minutes per week.

  • 4

    Individuals with MG are generally less physically active than healthy controls, with many failing to meet recommended activity levels.

  • 5

    The study aims to assess exercise patterns and perceived impacts of physical activity on well-being and MG symptoms, considering various demographic factors.

Original Source(s)

Impact of Exercise on Myasthenia Gravis: Insights from a Patient-Reported Survey on Activity Patterns and Effects

  • by Stefanie Glaubitz, Stefanie Meyer, Johanna Loris, Rachel Zeng, Karsten Kummer, Tania Garfias-Veitl, Ariana Seraji, Lina Hassoun, Denise Rohleder, Ina Hunger, Jana Zschüntzsch

  • December 17, 2025

Related Content

FDA Clears Exoskeleton for Spinal Cord Injury

Use is limited to level indoor and adjoining outdoor areas and requires supervision by a companion with specialized training.

Neurologists lead advancements in care and research at annual meeting

At AAN 2025, UC Irvine researchers showcase cutting-edge studies spanning AI, brain injury, and rare diseases.

  • September 16, 2025

  • 1 min
FDA approves first therapy for Alexander disease

The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.